<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03417570</url>
  </required_header>
  <id_info>
    <org_study_id>201708210</org_study_id>
    <nct_id>NCT03417570</nct_id>
  </id_info>
  <brief_title>Cap Assisted Upper Endoscopy Versus High Definition White Light Endoscopy and Narrow Band Imaging Alone In The Detection Of Visible Lesions Barrett's Esophagus: A Randomized Tandem Study</brief_title>
  <official_title>Cap Assisted Upper Endoscopy Versus High Definition White Light Endoscopy and Narrow Band Imaging Alone In The Detection Of Visible Lesions Barrett's Esophagus: A Randomized Tandem Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that the addition of a transparent cap to the end of the endoscope will
      increase the detection and diagnostic yield of visible lesions in Barrett's esophagus. Thus,
      the goal of this tandem design trial is to compare the diagnostic yield (DY) of cap assisted
      endoscopy with that of conventional endoscopy using high definition-white light endoscopy
      (HD-WLE) and narrow band imaging (NBI) in patients with Barrett's esophagus.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 22, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the diagnostic yield of EGD with HD-WLE and NBI to the diagnostic yield of cap-assisted EGD with HD-WLE and NBI</measure>
    <time_frame>At the time of procedure (day 1)</time_frame>
    <description>-Diagnostic yield is defined as the proportion of EGD in which visible Barrett's esophagus lesions were identified and confirmed histologically as low grade dysplasia, high grade dysplasia, intramucosal cancer, or invasive adenocarcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of visible lesions detected per person in EGD with cap versus without cap</measure>
    <time_frame>At the time of procedure (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases of high grade dysplasia and esophageal adenocarcinoma detected by the EGD with cap versus the EGD without cap</measure>
    <time_frame>At the time of procedure (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedure duration in minutes</measure>
    <time_frame>At the time of procedure (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by procedure-related adverse events</measure>
    <time_frame>Through 48 hours after EGD</time_frame>
    <description>-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Barrett Esophagus</condition>
  <arm_group>
    <arm_group_label>Arm 1: EGD with cap first, followed by EGD without cap</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Participants in the first arm will undergo EGD with cap first, followed by EGD without cap.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: EGD without cap first, followed by EGD with cap</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Participants in the second arm will undergo EGD without cap first, followed by EGD with cap</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)</intervention_name>
    <description>-The second endoscopist will be blinded to the results of the initial exam.</description>
    <arm_group_label>Arm 1: EGD with cap first, followed by EGD without cap</arm_group_label>
    <arm_group_label>Arm 2: EGD without cap first, followed by EGD with cap</arm_group_label>
    <other_name>EGD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Olympus Disposable Distal Attachment Cap</intervention_name>
    <description>-The second endoscopist will be blinded to the results of the initial exam.</description>
    <arm_group_label>Arm 1: EGD with cap first, followed by EGD without cap</arm_group_label>
    <arm_group_label>Arm 2: EGD without cap first, followed by EGD with cap</arm_group_label>
    <other_name>Cap</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be at least 18 years of age.

          -  Must be patients undergoing standard of care EGD for the confirmation of dysplasia in
             BE or EET for dysplasia in BE.

          -  Must be able to understand and willing to sign an IRB-approved written informed
             consent document.

        Exclusion Criteria:

          -  Pregnant or breastfeeding.

          -  Presence of erosive esophagitis.

          -  Prior endoscopic treatment for BE.

          -  Unable to tolerate sedation due to medical comorbidities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir M Kushnir, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California - Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

